To explore the comparative effectiveness of partial nephrectomy (PN), radical nephrectomy (RN), ablative therapies (ablation) and active surveillance (AS) for small renal masses (SRMs; tumour diameter ≤4.0 cm) in the domains of survival, renal function and quality of life (QoL) using the prospectively maintained Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry.
Introduction
Nephron-sparing strategies have increasingly gained traction for the management of localised renal masses to reduce the risk of chronic kidney disease (CKD) and its associated comorbidities [1, 2] . As such, the AUA issued guideline statements in 2017 for the management of localised renal masses suspicious for cancer [3] . The guideline committee reviewed the evidence of four contemporary approaches in the management of clinical stage T1a tumours (diameter ≤4.0 cm): partial nephrectomy (PN), radical nephrectomy (RN), ablative therapies (ablation) and active surveillance (AS). Whilst oncological outcomes remain the priority of management, additional endpoints such as renal function and quality of life (QoL) were recognised as important considerations.
A 2016 meta-analysis compared the oncological and functional outcomes of these management strategies in a head-to-head fashion [4] . Whilst the strength of evidence was often low-to-moderate for direct comparisons of interventional approaches (PN, RN or ablation), the paucity of data regarding AS rendered analysis of this method largely insufficient to draw conclusions. As a result, the AUA guidelines committee and a systematic review of research gaps acknowledged a need to prioritise prospective studies comparing the effectiveness of these various approaches in patients with localised renal masses [3, 5] .
The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry is a multi-institutional, prospective trial established in 2009 to evaluate the safety of AS compared to primary intervention for patients with small renal masses (SRMs), defined as clinical stage T1a tumours [6] . Whilst early reports have compared oncological and functional outcomes between AS and intervention, none have evaluated if differences exist amongst the three different interventional approaches [6] [7] [8] . Thus, the present study aimed to evaluate the comparative effectiveness of PN, RN, ablation and AS on the outcomes of survival, renal function and QoL in a prospective cohort.
Patients and Methods

Study design and data collection
Since 1 January 2009, the multi-institutional DISSRM Registry has prospectively enrolled patients aged ≥18 years who choose to undergo AS or intervention for a clinically localised, solid, contrast-enhancing renal mass of ≤4.0 cm in diameter on axial imaging. Full study design, selection criteria and surveillance protocol have been previously described [6, 9] . This study was approved by the Institutional Review Board.
Management options for SRMs included PN, RN, ablation and AS. Patients choosing AS were monitored with repeat imaging every 6-12 months, and intervention was recommended upon evidence of progression, which was defined as a growth rate >0.5 cm/year or tumour diameter of >4 cm. Alternatively, patients could choose to pursue delayed intervention at their own discretion.
The estimated GFR (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation from creatinine values obtained at enrolment, and at the 6-and 12-month follow-ups [10] . The validated Short Form 12 (SF-12) questionnaire was administered to estimate self-reported QoL at enrolment, and at the 6-and 12-month follow-ups, and every year thereafter [7, 11] . The SF-12 is comprised of a physical component summary (PCS) and mental component summary (MCS).
Statistical analysis
Baseline patient and tumour characteristics were compared across the four management groups using ANOVA with Bonferroni correction and the chi-squared test. Survival outcomes were estimated using the Kaplan-Meier approach and compared using the log-rank test. Cox proportional hazards regression was used to identify variables associated with survival. The mixed-effects model was used for eGFR and QoL analysis, in which linear regression was performed for continuous outcomes and logistic regression was performed for binary outcomes. Statistical significance was set at a = 0.05, and analyses were performed using Stata version 13.1 (StataCorp, College Station, TX, USA).
Results
Patient characteristics
At the time of administrative censoring, 638 patients were enrolled in the DISSRM Registry: 299 patients (46.9%) chose intervention, whereas 339 (53.1%) chose AS. Within the intervention group, 231 (36.2% of entire cohort) patients received PN, 41 (6.4%) RN and 27 (4.2%) ablation. Baseline patient characteristics are detailed in Table S1 . Notably, PN patients were younger and had less comorbidity than all the other groups. Furthermore, RN patients were more likely to have high complexity tumours, whereas ablation patients had more low complexity tumours, as defined by the R.E.N.A.L. (Radius; Exophytic/Endophytic; Nearness; Anterior/Posterior; Location) nephrometry score. There were a total of 46 patients (13.6% of AS patients) who underwent delayed intervention: 29 (63.0% of delayed intervention patients) received PN, five (10.9%) RN and 12 (26.1%) ablation. Over half of the delayed intervention cases were performed electively, with no indication of clinical progression (Fig. S1) . Of the patients who demonstrated progression, the vast majority were found based on a growth rate >0.5 cm/year. The pathological outcomes of patients who underwent intervention or biopsy are listed in Table S2 . Most patients who underwent primary or delayed intervention had lowgrade (Fuhrman Grade 1-2) clear cell RCC. Amongst AS patients who underwent biopsy but did not undergo subsequent intervention, the most common histological finding was oncocytoma.
Survival outcomes
The median (interquartile range [IQR]) follow-up time was 3.0 (1.6-5.0) years, and 158 patients (24.7%) were followed for ≥5 years. There were 40 deaths (6.3%) in the registry. Two deaths were due to high-grade RCC (Fuhrman Grade 3-4), and both patients developed metastasis after undergoing PN as a primary intervention. Cancer-specific survival (CSS) was 98.8% in the PN group and 100% in all other groups at 7 years of follow-up (Fig. 1A) . There was no statistically significant difference in CSS amongst the four management groups (log-rank P = 0.5).
Overall survival (OS) was significantly lower in the AS group (66.1% at 7 years) compared to all three intervention groups (log-rank P = 0.005) (Fig. 1B) . Amongst the PN, RN and ablation groups, where OS was 87.9%, 90.2% and 83.5% at 7 years, respectively, there was no significant difference in OS (log-rank P = 0.3). Unadjusted regression of intervention type on the outcome of all-cause mortality showed an increased hazard of death with AS (hazard ratio [HR] 3.27, 95% CI 1.55-6.92, P = 0.002) ( Table 1 ). However, adjustment for age, sex and Charlson Comorbidity Index (CCI) showed that AS, as a management strategy, was not independently associated with worse OS compared to any of the intervention groups (HR 1.66, 95% CI 0.72-3.81, P = 0.2). Instead, older age and higher CCI were associated with an increased hazard of allcause mortality. 
Renal function outcomes
The eGFR was calculated from 762 creatinine values obtained from 381 patients, including 140 PN patients, 38 RN patients, 27 ablation patients and 176 AS patients (Table S3) .
Comparisons of the management groups showed that RN patients had worse absolute renal function than PN and ablation patients at enrolment, and at the 6-and 12-month follow-ups ( Fig. 2 ). RN patients also had lower eGFRs than AS patients at the 6-and 12-month follow-ups. Finally, AS patients had lower eGFR than PN patients at enrolment and at the 6-month follow-up.
Within management groups, renal function also changed significantly over time. PN patients had, on average, a decline of 8.9 mL/min/1.73 m 2 in eGFR at 12 months when compared to enrolment (P = 0.03). RN patients had a decline in eGFR of 36.5 mL/min/1.73 m 2 at 6 months and 21.9 mL/ min/1.73 m 2 at 12 months when compared to enrolment (P < 0.001 and P = 0.05, respectively), but the interval improvement was not statistically significant (14.6 mL/min/ 1.73 m 2 , P = 0.5).
Multivariable mixed-effects linear regression models evaluated the relative change in eGFR. The impact of adjusting for baseline eGFR is shown by inclusion of this factor in Model 2, which attenuated the drop in eGFR for RN compared to PN patients from À11.82 mL/min/1.73 m 2 to À4.52 mL/min/ 1.73 m 2 (Table 2) . Notably, each additional month of followup was associated with an overall decline in eGFR. Model 2 also showed a statistically significant decrease in eGFR for PN patients compared to AS patients. Finally, higher baseline eGFR was associated with higher final eGFR, but the associations with age, race and comorbidities were no longer significant after adjustment for baseline eGFR.
Multivariable mixed-effects logistic regression was performed to determine the odds of clinically significant CKD, defined as an eGFR of <45 mL/min/1.73 m 2 (CKD stage ≥3B). Similar to the outcome for change in eGFR, adjustment for baseline GFR in Model 2 decreased the magnitude of effect but still showed that RN was associated with a higher odds of clinically significant CKD compared to PN (odds ratio [OR] 10.92, 95% CI 3.08-38.77, P < 0.001). Notably, higher baseline eGFR was associated with lower odds of experiencing clinically significant CKD. AS and PN had similar rates of CKD ≥3B after adjustment for baseline eGFR. No patients were initiated on renal replacement therapy during follow-up.
QoL outcomes
A total of 1957 surveys were collected over a span of 7 years, completed by 218 PN patients, 43 RN patients, 37 ablation (Table S4 ). The median (IQR) time to questionnaire follow-up after enrolment was 1 ( 0-2) year, with 232 patients (36.4%) achieving ≥3 years of follow-up.
Total SF-12 scores were significantly lower amongst AS patients only when compared to PN patients at enrolment, and at the 2-and 3-year follow-ups (Fig. 3A) . Mixed-effects regression showed lower scores in AS patients when compared to PN patients (À3.23 points, 95% CI À5.99 to À0.47, P = 0.02) after controlling for time, age, gender, CCI and body mass index (BMI) ( Table 3) . Notably, female gender, increased CCI and increased BMI were associated with lower total SF-12 scores.
PCS scores were significantly lower amongst AS patients when compared to PN patients at enrolment and annually until year 5 (Fig. 3B) . Multivariable mixed-effects regression showed lower scores amongst AS patients compared to PN patients (À3.24 points, 95% CI À5.10 to À1.37, P = 0.001). In addition to female gender, increased CCI and increased BMI, each additional year of follow-up and an older age at enrolment were associated with significantly lower PCS scores.
MCS scores were comparable across all groups at each point of follow-up (Fig. 3C) . On multivariable mixed-effects regression, MCS scores were higher with each additional year of follow-up, with older age at enrolment and for males. Notably, there were no significant differences in MCS scores amongst any of the management groups.
An analysis of the delayed intervention patients found that there were no significant differences in total SF-12, PCS or MCS scores following intervention after a period of AS. However, it should be noted that this cohort was limited in size and the number of data points both before and after intervention was highly variable amongst patients.
Discussion
The present study directly compares the four major management options for SRMs in the domains of survival, renal function and QoL in a prospective, contemporaneous registry. To summarise, CSS was excellent and comparable in all groups, but OS was lower in AS patients and likely attributable to older age and increased comorbidities. Renal function was lowest in RN patients but comparable in all other groups. QoL was lowest in AS patients due to lower physical health scores, but mental health scores were similar in all groups. These data address a number of the research gaps previously identified by demonstrating outcomes in a prospective manner, thereby strengthening the rationale behind recent AUA guidelines, which were based on retrospective studies [3, 5] .
In the present cohort of patients with clinical stage T1a tumours, CSS was similar regardless of management. Likewise, data from a randomised controlled trial (RCT) and recent meta-analysis found no significant difference in oncological outcomes for patients treated with PN vs RN [4, 12] . In conjunction, these results show that CSS is determined by stage; therefore, all SRMs would be expected to have similar rates of CSS. Furthermore, longer follow-up from this registry confirms the continued safety of AS compared to various options for intervention in carefully selected patients -namely those who are older and have increased comorbidities [6] . These factors probably explain the lower OS rate amongst AS patients and suggest that OS is driven primarily by comorbidity status, as previously demonstrated [4, 13, 14] .
Given the excellence of oncological outcomes, the focus has increasingly shifted to preservation of renal function as a secondary goal. Indeed, the AUA guidelines recommend PN over RN when intervention is indicated to mitigate the risk of CKD progression [3] . A recent meta-analysis suggested RN patients exhibit the lowest eGFR when compared to PN, ablation and AS patients, but the evidence was wrought with retrospective data reporting results at non-standardised time points [5, 15] . Nevertheless, the report found that when compared to PN patients, RN patients had a lower final eGFR (À10.5 mL/min/1.73 m 2 , 95% CI À9.8 to À11.2, P < 0.001) and a higher risk of CKD stage ≥3 (relative risk 2.56, 95% CI 1.97-3.32, P < 0.001). The only RCT to date evaluating CKD outcomes with OS found that there were no differences between patients undergoing RN vs PN, despite significantly worse renal function in the RN group [12] . Although no explanation could be given at the time, recent studies from the Cleveland Clinic have shown that patients with CKD induced by surgery behave more like patients without CKD than those with medically induced CKD, with the latter group demonstrating worse survival outcomes [16, 17] . Under this paradigm, in which surgically induced CKD and medically induced CKD are categorically different pathologies, RN patients would be expected to have similar survival outcomes when compared to PN patients, despite the significantly worse renal function. Like the RCT, the present study demonstrates this effect and potentially strengthens the observations from the Cleveland Clinic.
In the meta-analysis, no differences in renal function were found between PN and ablation patients, but data were insufficient to compare either intervention against the AS group [15] . Results from the present study corroborate these retrospective findings in a prospective cohort but also provide insight into direct comparisons of renal function to AS, which was previously found not to preserve eGFR any better than PN or ablation [8, 18] . Importantly, our present results show that AS patients, despite having lower baseline eGFR, have similar or improved renal functional outcomes compared to PN and ablation patients when controlling for patient characteristics and time. Potential explanations point to recent evidence suggesting that baseline eGFR may exert an effect on final eGFR [16, 17, 19, 20] . Intuitively, patients with higher baseline eGFR may be thought to be protected from renal functional decline and those with compromised renal function may stand to benefit the most from nephronsparing approaches. Therefore, we included two models for both the linear and logistic regressions to reflect this new paradigm, where Model 2 included baseline eGFR as an independent variable. Adjustment for baseline eGFR reduced the variability in the effect measure sufficiently to show that AS was associated with better preservation of absolute eGFR compared to PN. At the same time, adjustment in the logistic model demonstrated that it was the lower baseline eGFR in the AS group and a general decrease in eGFR over time for all patients that made it appear as though AS patients had a greater rate of CKD stage ≥3B in Model 1, whereas similar rates were observed for both AS and PN in Model 2.
To date, only four studies have attempted QoL comparisons in patients undergoing PN vs RN [21] [22] [23] [24] . Results generally found that patients undergoing PN scored higher on physical functioning than patients undergoing RN. Although our present findings were not significant, we found a similar trend. On the other hand, AS patients scored significantly lower than PN patients in overall QoL, which was primarily driven by the physical health component. Even after adjustment for other factors, this difference remains and is present at enrolment, underscoring the favourable physical health status amongst PN patients. Importantly, the present study demonstrates that mental health scores improved with each year of follow-up, independent of management type. While the trend was suggested in a prior report, it was not statistically significant, and the present study provides longer follow-up with more granular comparisons amongst the different types of intervention [7] .
Limitations of the present study include the selection bias associated with the non-randomised design of the registry. Patient selection was intentionally designed to optimise outcomes for AS patients in order to represent comparative effectiveness in clinical practice. Furthermore, renal mass biopsy has not been a requirement to enrol in the registry and may therefore introduce heterogeneity in the patient population with respect to the presence of benign lesions. While this reflects the current standard of practice, it is notable that survival may be overestimated [25] [26] [27] . However, with no significant difference in biopsy rate between intervention and AS groups, any overestimation that may exist should be distributed equally and randomly. Nevertheless, results from the present study serve to demonstrate effectiveness and reflect practice patterns, in which shared decision-making is encouraged, as opposed to efficacy in an artificially controlled setting. Finally, it should be noted that missing eGFR and QoL data may introduce additional selection bias as well.
Conclusions
Data from the present study prospectively address research gaps identified by the AUA. With excellent oncological outcomes in all groups, it is reasonable to consider AS for SRMs, especially in older patients with multiple comorbidities. However, if intervention is indicated, nephronsparing approaches like PN or ablation are favoured over RN due to improved renal functional outcomes. Finally, AS patients have lower QoL scores, probably due to worse health at baseline. Notably, mental health is comparable in all groups and improves with time. The present results confirm previous comparisons between PN and RN, whilst concurrently describing the comparative effectiveness of two relatively new options, ablation and AS, for patients enrolled in the same time frame. 
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